FPI Based Hyperspectral Imager for the Complex Surfaces—Calibration, Illumination and Applications

Hyperspectral imaging (HSI) applications for biomedical imaging and dermatological applications have been recently under research interest. Medical HSI applications are non-invasive methods with high spatial and spectral resolution. HS imaging can be used to delineate malignant tumours, detect invasions, and classify lesion types. Typical challenges of these applications relate to complex skin surfaces, leaving some skin areas unreachable. In this study, we introduce a novel spectral imaging concept and conduct a clinical pre-test, the findings of which can be used to develop the concept towards a clinical application. The SICSURFIS spectral imager concept combines a piezo-actuated Fabry–Pérot interferometer (FPI) based hyperspectral imager, a specially designed LED module and several sizes of stray light protection cones for reaching and adapting to the complex skin surfaces. The imager is designed for the needs of photometric stereo imaging for providing the skin surface models (3D) for each captured wavelength. The captured HS images contained 33 selected wavelengths (ranging from 477 nm to 891 nm), which were captured simultaneously with accordingly selected LEDs and three specific angles of light. The pre-test results show that the data collected with the new SICSURFIS imager enable the use of the spectral and spatial domains with surface model information. The imager can reach complex skin surfaces. Healthy skin, basal cell carcinomas and intradermal nevi lesions were classified and delineated pixel-wise with promising results, but further studies are needed. The results were obtained with a convolutional neural network

FPI Based Hyperspectral Imager for the Complex Surfaces—Calibration, Illumination and Applications

Hyperspectral imaging (HSI) applications for biomedical imaging and dermatological applications have been recently under research interest. Medical HSI applications are non-invasive methods with high spatial and spectral resolution. HS imaging can be used to delineate malignant tumours, detect invasions, and classify lesion types. Typical challenges of these applications relate to complex skin surfaces, leaving some skin areas unreachable. In this study, we introduce a novel spectral imaging concept and conduct a clinical pre-test, the findings of which can be used to develop the concept towards a clinical application. The SICSURFIS spectral imager concept combines a piezo-actuated Fabry–Pérot interferometer (FPI) based hyperspectral imager, a specially designed LED module and several sizes of stray light protection cones for reaching and adapting to the complex skin surfaces. The imager is designed for the needs of photometric stereo imaging for providing the skin surface models (3D) for each captured wavelength. The captured HS images contained 33 selected wavelengths (ranging from 477 nm to 891 nm), which were captured simultaneously with accordingly selected LEDs and three specific angles of light. The pre-test results show that the data collected with the new SICSURFIS imager enable the use of the spectral and spatial domains with surface model information. The imager can reach complex skin surfaces. Healthy skin, basal cell carcinomas and intradermal nevi lesions were classified and delineated pixel-wise with promising results, but further studies are needed. The results were obtained with a convolutional neural network

Differentiating Malignant from Benign Pigmented or Non-Pigmented Skin Tumours—A Pilot Study on 3D Hyperspectral Imaging of Complex Skin Surfaces and Convolutional Neural Networks

Several optical imaging techniques have been developed to ease the burden of skin cancer disease on our health care system. Hyperspectral images can be used to identify biological tissues by their diffuse reflected spectra. In this second part of a three-phase pilot study, we used a novel hand-held SICSURFIS Spectral Imager with an adaptable field of view and target-wise selectable wavelength channels to provide detailed spectral and spatial data for lesions on complex surfaces. The hyperspectral images (33 wavelengths, 477–891 nm) provided photometric data through individually controlled illumination modules, enabling convolutional networks to utilise spectral, spatial, and skin-surface models for the analyses. In total, 42 lesions were studied: 7 melanomas, 13 pigmented and 7 intradermal nevi, 10 basal cell carcinomas, and 5 squamous cell carcinomas. All lesions were excised for histological analyses. A pixel-wise analysis provided map-like images and classified pigmented lesions with a sensitivity of 87% and a specificity of 93%, and 79% and 91%, respectively, for non-pigmented lesions. A majority voting analysis, which provided the most probable lesion diagnosis, diagnosed 41 of 42 lesions correctly. This pilot study indicates that our non-invasive hyperspectral imaging system, which involves shape and depth data analysed by convolutional neural networks, is feasible for differentiating between malignant and benign pigmented and non-pigmented skin tumours, even on complex skin surfaces

Differentiating Malignant from Benign Pigmented or Non-Pigmented Skin Tumours—A Pilot Study on 3D Hyperspectral Imaging of Complex Skin Surfaces and Convolutional Neural Networks

Several optical imaging techniques have been developed to ease the burden of skin cancer disease on our health care system. Hyperspectral images can be used to identify biological tissues by their diffuse reflected spectra. In this second part of a three-phase pilot study, we used a novel hand-held SICSURFIS Spectral Imager with an adaptable field of view and target-wise selectable wavelength channels to provide detailed spectral and spatial data for lesions on complex surfaces. The hyperspectral images (33 wavelengths, 477–891 nm) provided photometric data through individually controlled illumination modules, enabling convolutional networks to utilise spectral, spatial, and skin-surface models for the analyses. In total, 42 lesions were studied: 7 melanomas, 13 pigmented and 7 intradermal nevi, 10 basal cell carcinomas, and 5 squamous cell carcinomas. All lesions were excised for histological analyses. A pixel-wise analysis provided map-like images and classified pigmented lesions with a sensitivity of 87% and a specificity of 93%, and 79% and 91%, respectively, for non-pigmented lesions. A majority voting analysis, which provided the most probable lesion diagnosis, diagnosed 41 of 42 lesions correctly. This pilot study indicates that our non-invasive hyperspectral imaging system, which involves shape and depth data analysed by convolutional neural networks, is feasible for differentiating between malignant and benign pigmented and non-pigmented skin tumours, even on complex skin surfaces

Growth Patterns in Young Adult Monozygotic Twin Pairs Discordant and Concordant for Obesity

Telah dl1akukan penelotian kemungkinan penggunaan pati ketela rambat sebahaibahan penghancur pembuatan tablet

Effects of dapagliflozin on symptoms, function and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial

Background: Goals of management in patients with heart failure and reduced ejection fraction include reducing death and hospitalizations, and improving health status (symptoms, physical function, and quality of life). In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure), sodium–glucose cotransporter-2 inhibitor, dapagliflozin, reduced death and hospitalizations, and improved symptoms in patients with heart failure and reduced ejection fraction. In this analysis, we examine the effects of dapagliflozin on a broad range of health status outcomes, using the Kansas City Cardiomyopathy Questionnaire (KCCQ). Methods: KCCQ was evaluated at randomization, 4 and 8 months. Patients were divided by baseline KCCQ total symptom score (TSS); Cox proportional hazards models examined the effects of dapagliflozin on clinical events across these subgroups. We also evaluated the effects of dapagliflozin on KCCQ-TSS, clinical summary score, and overall summary score. Responder analyses were performed to compare proportions of dapagliflozin versus placebo-treated patients with clinically meaningful changes in KCCQ at 8 months. Results: A total of 4443 patients had available KCCQ at baseline (median KCCQ-TSS, 77.1 [interquartile range, 58.3–91.7]). The effects of dapagliflozin vs placebo on reducing cardiovascular death or worsening heart failure were consistent across the range of KCCQ-TSS (lowest to highest tertile: hazard ratio, 0.70 [95% CI, 0.57–0.86]; hazard ratio, 0.77 [95% CI, 0.61–0.98]; hazard ratio, 0.62 [95% CI, 0.46–0.83]; P for heterogeneity=0.52). Patients treated with dapagliflozin had greater improvement in mean KCCQ-TSS, clinical summary score, and overall summary score at 8 months (2.8, 2.5 and 2.3 points higher versus placebo; P<0.0001 for all). Fewer patients treated with dapagliflozin had a deterioration in KCCQ-TSS (odds ratio, 0.84 [95% CI, 0.78–0.90]; P<0.0001); and more patients had at least small, moderate, and large improvements (odds ratio, 1.15 [95% CI, 1.08–1.23]; odds ratio, 1.15 [95% CI, 1.08–1.22]; odds ratio, 1.14 [95% CI, 1.07–1.22]; number needed to treat=14, 15, and 18, respectively; P<0.0001 for all; results consistent for KCCQ clinical summary score and overall summary score). Conclusions: Dapagliflozin reduced cardiovascular death and worsening heart failure across the range of baseline KCCQ, and improved symptoms, physical function, and quality of life in patients with heart failure and reduced ejection fraction. Furthermore, dapagliflozin increased the proportion of patients experiencing at least small, moderate, and large improvements in health status; these effects were clinically important

Review of retrospective dosimetry techniques for external ionising radiation exposures

The current focus on networking and mutual assistance in the management of radiation accidents or incidents has demonstrated the importance of a joined-up approach in physical and biological dosimetry. To this end, the European Radiation Dosimetry Working Group 10 on 'Retrospective Dosimetry' has been set up by individuals from a wide range of disciplines across Europe. Here, established and emerging dosimetry methods are reviewed, which can be used immediately and retrospectively following external ionising radiation exposure. Endpoints and assays include dicentrics, translocations, premature chromosome condensation, micronuclei, somatic mutations, gene expression, electron paramagnetic resonance, thermoluminescence, optically stimulated luminescence, neutron activation, haematology, protein biomarkers and analytical dose reconstruction. Individual characteristics of these techniques, their limitations and potential for further development are reviewed, and their usefulness in specific exposure scenarios is discussed. Whilst no single technique fulfils the criteria of an ideal dosemeter, an integrated approach using multiple techniques tailored to the exposure scenario can cover most requirements. © The Author 2010. Published by Oxford University Press. All rights reserved